Literature DB >> 33499147

Investigation of Receptor Heteromers Using NanoBRET Ligand Binding.

Elizabeth K M Johnstone1,2,3, Heng B See1,2,3, Rekhati S Abhayawardana1,2,3, Angela Song4, K Johan Rosengren4, Stephen J Hill1,2,5,6, Kevin D G Pfleger1,2,3,7.   

Abstract

Receptor heteromerization is the formation of a complex involving at least two different receptors with pharmacology that is distinct from that exhibited by its constituent receptor units. Detection of these complexes and monitoring their pharmacology is crucial for understanding how receptors function. The Receptor-Heteromer Investigation Technology (Receptor-HIT) utilizes ligand-dependent modulation of interactions between receptors and specific biomolecules for the detection and profiling of heteromer complexes. Previously, the interacting biomolecules used in Receptor-HIT assays have been intracellular proteins, however in this study we have for the first time used bioluminescence resonance energy transfer (BRET) with fluorescently-labeled ligands to investigate heteromerization of receptors on the cell surface. Using the Receptor-HIT ligand binding assay with NanoBRET, we have successfully investigated heteromers between the angiotensin II type 1 (AT1) receptor and the β2 adrenergic receptor (AT1-β2AR heteromer), as well as between the AT1 and angiotensin II type 2 receptor (AT1-AT2 heteromer).

Entities:  

Keywords:  GPCR; NanoBRET; Nluc; Receptor-HIT; angiotensin receptor; heteromer; ligand binding; β2 adrenergic receptor

Mesh:

Substances:

Year:  2021        PMID: 33499147      PMCID: PMC7866079          DOI: 10.3390/ijms22031082

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  57 in total

1.  D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum.

Authors:  Asim J Rashid; Christopher H So; Michael M C Kong; Teresa Furtak; Mufida El-Ghundi; Regina Cheng; Brian F O'Dowd; Susan R George
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

2.  Effect of enhanced Renilla luciferase and fluorescent protein variants on the Förster distance of Bioluminescence resonance energy transfer (BRET).

Authors:  Helen Dacres; Michelle Michie; Jian Wang; Kevin D G Pfleger; Stephen C Trowell
Journal:  Biochem Biophys Res Commun       Date:  2012-08-01       Impact factor: 3.575

3.  Identification of membrane-bound variant of metalloendopeptidase neurolysin (EC 3.4.24.16) as the non-angiotensin type 1 (non-AT1), non-AT2 angiotensin binding site.

Authors:  Naomi J Wangler; Kira L Santos; Ines Schadock; Fred K Hagen; Emanuel Escher; Michael Bader; Robert C Speth; Vardan T Karamyan
Journal:  J Biol Chem       Date:  2011-10-28       Impact factor: 5.157

4.  Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation.

Authors:  Dominik Schelshorn; Fanny Joly; Sophie Mutel; Cornelia Hampe; Billy Breton; Vincent Mutel; Robert Lütjens
Journal:  Mol Pharmacol       Date:  2011-11-22       Impact factor: 4.436

5.  NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing.

Authors:  Carl W White; Elizabeth K M Johnstone; Heng B See; Kevin D G Pfleger
Journal:  Cell Signal       Date:  2018-11-22       Impact factor: 4.315

6.  Functional characterization of β2-adrenergic and insulin receptor heteromers.

Authors:  Maja Susec; Milan Sencanski; Sanja Glisic; Nevena Veljkovic; Christina Pedersen; Luka Drinovec; Jurij Stojan; Jane Nøhr; Milka Vrecl
Journal:  Neuropharmacology       Date:  2019-01-29       Impact factor: 5.250

7.  Rab1 GTPase and dimerization in the cell surface expression of angiotensin II type 2 receptor.

Authors:  Xiaoping Zhang; Guansong Wang; Denis J Dupré; Yumei Feng; Mélanie Robitaille; Eric Lazartigues; Ying-Hong Feng; Terence E Hébert; Guangyu Wu
Journal:  J Pharmacol Exp Ther       Date:  2009-04-08       Impact factor: 4.030

8.  Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization.

Authors:  Chiara Fiorentini; Chiara Busi; Emanuela Gorruso; Cecilia Gotti; Pierfranco Spano; Cristina Missale
Journal:  Mol Pharmacol       Date:  2008-04-18       Impact factor: 4.436

9.  Asymmetric Recruitment of β-Arrestin1/2 by the Angiotensin II Type I and Prostaglandin F2α Receptor Dimer.

Authors:  Dany Fillion; Dominic Devost; Rory Sleno; Asuka Inoue; Terence E Hébert
Journal:  Front Endocrinol (Lausanne)       Date:  2019-03-18       Impact factor: 5.555

Review 10.  NanoBRET: The Bright Future of Proximity-Based Assays.

Authors:  Natasha C Dale; Elizabeth K M Johnstone; Carl W White; Kevin D G Pfleger
Journal:  Front Bioeng Biotechnol       Date:  2019-03-26
View more
  3 in total

1.  Novel Pharmacology Following Heteromerization of the Angiotensin II Type 2 Receptor and the Bradykinin Type 2 Receptor.

Authors:  Elizabeth K M Johnstone; Mohammed Akli Ayoub; Rebecca J Hertzman; Heng B See; Rekhati S Abhayawardana; Ruth M Seeber; Kevin D G Pfleger
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-26       Impact factor: 6.055

Review 2.  Profiling novel pharmacology of receptor complexes using Receptor-HIT.

Authors:  Elizabeth K M Johnstone; Kevin D G Pfleger
Journal:  Biochem Soc Trans       Date:  2021-08-27       Impact factor: 5.407

Review 3.  GPCR heteromers: An overview of their classification, function and physiological relevance.

Authors:  Natasha C Dale; Elizabeth K M Johnstone; Kevin D G Pfleger
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-30       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.